Experimental group3:Baofukang suppository, high dose

2 trials

Sponsors

Beijing Tsinghua Changgeng Hospita

Conditions

HR-HPV16/18 infection with CINI/P16 negative CIN II

Phase 2

A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial on the efficacy and safety of Baofukang suppository in treating HR-HPV16/18 infection with CINI/P16 negativeCIN II

RecruitingChiCTR2100043957

Beijing Tsinghua Changgeng HospitaHR-HPV16/18 infection with CINI/P16 negative CIN II

Start: 2021-03-09Updated: 2021-07-12

A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial on the efficacy and safety of Baofukang suppository in treating HR-HPV16/18 infection with CINI/P16 negativeCIN II

RecruitingITMCTR2100004528

Beijing Tsinghua Changgeng HospitaHR-HPV16/18 infection with CINI/P16 negative CIN II

Start: 2021-03-09Updated: 2023-02-20